Endometrial cancers (EC) are categorized by the uncontrollable growth of malignant cells in the tissue of the endometrium. EC is the most common gynecologic malignancy in the developed world and is generally found in postmenopausal women. A majority of EC are diagnosed in the early stages (stages I and II) as they frequently produce abnormal vaginal bleeding and have a 5-year survival rate of 75%.
There have been many advancements in pathogenesis and molecular mechanisms of EC over the years. While most women are cured with surgery alone, women with recurrent or advanced-stage disease have limited treatment options and remain an area of unmet need. Identifying potential biomarkers through genetics screening has shown promise in identifying underlying molecular mechanisms. This aids in the advancement in prognosis and treatment of EC.
Modern research focuses on understanding the molecular mechanisms underlying ECs and their application in treatment. Developments of new therapies such as Primary Fertility-Sparing Therapy have shown positive outcomes while also preserving the uterus. These advancements in treatment show promise for individuals diagnosed with EC.
For this Research Topic, we welcome submissions of Original Research and Reviews highlighting the advancements in prognosis and therapeutics of Endometrial Cancers
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Endometrial cancers (EC) are categorized by the uncontrollable growth of malignant cells in the tissue of the endometrium. EC is the most common gynecologic malignancy in the developed world and is generally found in postmenopausal women. A majority of EC are diagnosed in the early stages (stages I and II) as they frequently produce abnormal vaginal bleeding and have a 5-year survival rate of 75%.
There have been many advancements in pathogenesis and molecular mechanisms of EC over the years. While most women are cured with surgery alone, women with recurrent or advanced-stage disease have limited treatment options and remain an area of unmet need. Identifying potential biomarkers through genetics screening has shown promise in identifying underlying molecular mechanisms. This aids in the advancement in prognosis and treatment of EC.
Modern research focuses on understanding the molecular mechanisms underlying ECs and their application in treatment. Developments of new therapies such as Primary Fertility-Sparing Therapy have shown positive outcomes while also preserving the uterus. These advancements in treatment show promise for individuals diagnosed with EC.
For this Research Topic, we welcome submissions of Original Research and Reviews highlighting the advancements in prognosis and therapeutics of Endometrial Cancers
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
